The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 350:943-945 February 26, 2004 Number 9
NextNext

Valsartan, Captopril, or Both in Myocardial Infarction

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Pfeffer, M. A.
-PubMed Citation
To the Editor: In their assessment of treatment with valsartan, captopril, or both in patients with myocardial infarction complicated by heart failure or left ventricular dysfunction (Nov. 13 issue),1 Pfeffer et al. calculate a hazard ratio for their patients by using an "imputed placebo." Because they include this hazard ratio in a figure with hazard ratios from other trials that were placebo-controlled (Figure 3 of the article), the message is conveyed — since figures are powerful — that this trial was also placebo-controlled. It was not. Two references supporting this depiction are provided in the article.2,3 These, and a subsequent . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.